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ABSTRACT
Objective: Little is known about the neuropsychological effects of risperidone in children
with pervasive developmental disorders.
Method: Twenty-four children (aged 5–17 years) with pervasive developmental disorders
and co-morbid disruptive behavior who responded favorably to open-label treatment with
risperidone as part of a previously described controlled discontinuation study completed two
different computerized attention tasks at baseline, weeks 4, 8, and 24 of open-label treatment,
and, at 8 weeks after random assignment to either placebo or risperidone. The primary effi-
cacy measures were response latencies to visually presented stimuli requiring two different
types of attention-controlled processing, i.e., focused and divided attention.
Results: About half of the clinical responders did not produce valid performance measures.
These could be shown to be of younger mental age and less adaptive as measured by the
Vineland Behavior Scales. For the valid task performers divided attention (serial search in
working memory) was shown to regress in the placebo group (n = 7), while in the risperidone
group (n = 7) there was further improvement. No such group difference was found for fo-
cused attention.
Conclusions: The study suggests a beneficial effect of risperidone after several months of
treatment, enhancing divided attention in children with pervasive developmental disorders.
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INTRODUCTION
IN CHILDREN AND ADOLESCENTS, the antipsychoticagent risperidone is increasingly being pre-
scribed to ameliorate disturbed behavior in a
variety of clinical conditions (Patel et al. 2005).
Risperidone has a now well-established effi-
cacy on severe tantrums, aggression, and self-
injurious behavior in children with pervasive
developmental disorders (PDDs) and also
leads to improvements in the repetitive and
stereotyped symptom domain (RUPP 2002;
McDougle et al. 2005; RUPP 2005). As a wor-
rying side effect, however, the use of risperi-
done may be associated with sedation (Aman
et al. 2005). This could lead to cognitive dys-
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2Department of Child Psychiatry and Rudolf Magnus Institute for Neuroscience, University Medical Center
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functions that may well interfere with perfor-
mance at school with consequently unwanted
stagnations in social, emotional, and cogni-
tive development. On the other hand, seda-
tive effects of risperidone frequently appear
to be limited to the first weeks of treatment,
while, moreover, risperidone may even have
the potential to improve cognitive function-
ing. For example, in schizophrenia, atypical
antipsychotic medications have been reported
to have beneficial effects on a variety of cogni-
tion domains, including executive functions,
vigilance, serial verbal learning, and complex
visuo-motor skills (Keefe et al. 1999; Harvey et
al. 2003). Interestingly, attention-related exec-
utive dysfunctions, among which is impaired
working memory, have been proposed to un-
derlie the core deficits of autism (Althaus
et al. 1996; Benetto et al. 1996; Pierce et al.
1997; Althaus et al. 1999; Landa and Goldberg
2005).
In children, there is a lack of studies to ad-
dress the neuropsychological effects of the
atypical antipsychotics. In the case of the most
widely used atypical agent risperidone, we
know of only two studies in children with sub-
average IQs who were treated for disruptive
behavior disorders. In these studies of the
Risperidone Disruptive Behavior Study Group,
the degree of sedation was mild and not asso-
ciated with cognitive deterioration (Turgay et
al. 2002; Findling et al. 2004). In fact, there
were similar improvements in tests for verbal
learning, attention, and memory as reported
for adult patients with schizophrenia. How-
ever, further evaluation of the neuropsycho-
logical effects of risperidone in the pediatric
population is warranted. The primary aim of
the present study was to examine the short-
and long-term impact of risperidone on cogni-
tive functioning in children and adolescents
with pervasive developmental disorders in a
previously described placebo-controlled dis-
continuation design. We expected that cogni-
tive performance of clinical responders to
risperidone would benefit from medication,
and hypothesized that (after 6 months of open-
label treatment) those patients who continued
on risperidone would be significantly less
likely to experience worsening of performance
in a computerized cognitive task compared to
those randomized to placebo.
METHODS AND MATERIALS
Subjects
Recruitment, clinical measures, and charac-
teristics of study participants have been de-
scribed in detail previously (Troost et al. 2005).
Study participants were recruited from re-
ferred patients of the Groningen and Utrecht
University Child and Adolescent Psychiatry
Centers, and could be either inpatients or
outpatients. All of the children had to meet
Diagnostic and Statistical Manual of Mental Dis-
orders, 4th edition, text revision (DSM-IV-TR)
criteria for a pervasive developmental disor-
der (American Psychiatric Association 2000).
These diagnoses were made by use of the Au-
tism Diagnostic Interview—Revised (Lord et
al. 1994) complemented with a clinical judg-
ment. Moreover, patients were required to
demonstrate significant co-morbid tantrums,
aggression, or self-injurious behavior. The aim
and procedure of the study were fully ex-
plained to the subjects and their parents be-
fore the parent’s written consent was
requested. If the subject was 12 year old or
older, then the written informed consent of the
parents was obtained along with that of the
patient. Twenty four subjects (age range 5–17
years) who were all clinical responders to
open-label treatment with risperidone were
randomly assigned after 24 weeks of treatment
to either gradual tapering to placebo or the
continued use of risperidone.
Neuropsychological tasks
Two different computerized choice-reaction
tasks from the de Sonneville Visual Attention
Task Battery (De Sonneville 1993) were em-
ployed at baseline (prestudy), during open-
label treatment with risperidone (weeks 4, 8,
and 24), and after randomization to either
placebo or continued use of risperidone (week
32 or last visit in case of early termination
because of significant worsening on clinical
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and parent-based measures as previously de-
scribed).
The first task was a focused attention task
designed to measure the degree of distractibil-
ity by irrelevant information. In this task, there
are three conditions, each consisting of a num-
ber of stimulus presentations (trials) the chil-
dren are required to respond to by pressing
one of the two mouse buttons, representing a
“yes” response or a “no” response, respec-
tively. “Yes” responses are to be given with the
index finger of the dominant hand and “no”
responses with the index finger of the other
hand. All stimuli are presented on a 17-inch
personal computer screen. The stimuli are four
pieces of fruit located at the corners of a virtual
diamond. Children must press the “yes” but-
ton whenever a previously presented target
(e.g., a cherry) occurs at one of the vertical po-
sitions of the diamond. These positions are
told to be the only ones that should be paid at-
tention to (relevant positions). The children
are required to press the “no” button in case
the target fruit is absent as well as whenever
the target occurs at one of the (horizontal) po-
sitions they actually are required to ignore (ir-
relevant positions); these trials are called
irrelevant target trials. There are 28 relevant
target trials, 14 irrelevant target trials (so-
called foils), and 14 nontarget trials. The three
types of trials are presented in a random se-
quence.
If there is any distraction by the target
occurring at one of the irrelevant positions, re-
action times (RTs) for correctly rejecting irrele-
vant targets will be slower than reaction times
to relevant targets. Distraction, moreover, may
lead to incorrectly pressing the “yes” response
key, this being denoted as a false alarm to an
irrelevant target.
Dependent measures of this task are condi-
tion-dependent error rates as measures of ac-
curacy, including the percentage of relevant
targets missed (PM), the percentage of false
alarms to relevant nontargets (PFNT), and the
percentage of false alarms to irrelevant targets
(PFIT) as well as mean RTs for the correct re-
sponses to the relevant targets (hits: RTRT), the
relevant nontargets (RTRNT), and the irrele-
vant targets (RTIT).
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The second task was a divided attention, or
memory search task designed to measure ser-
ial search processes that are carried out in
working memory (Schneider and Shiffrin
1977; Shiffrin and Schneider 1977). The task
consists of two blocks containing 40 trials
each. During the first block, one stimulus (i.e.,
a particular animal) has to be kept in mind
(target). This has to be compared with subse-
quently displayed sets of four stimuli (again
animals). These “display sets” may or may not
contain the target. A “yes” response (to be
given again with the index finger of the domi-
nant hand) is required whenever the target
makes part of the display set, otherwise a “no”
response must be given (with the index finger
of the nondominant hand). Fifty percent of the
trials contain the target, the other 50% do not.
Target and nontarget trials are randomly dis-
tributed. During the second task block, two
stimuli (animals) have to be kept in mind.
Whenever one of the memorized stimuli ap-
pears in the successively displayed sets of four
animals, a “yes” response is required, other-
wise again a “no” response must be given. In
this block again, half of the trials (n = 20) con-
tain the target.
The important manipulations are the num-
ber of stimuli to be kept in mind (memory
load) and target appearance. In general, the
correct rejection times of nontarget trials will
be longer than the reaction times of responses
to target trials (hits). This is because in the lat-
ter condition memory search is terminated as
soon as the target has been detected, whereas
it is exhaustive when the target is absent and
all comparisons with the stimulus/stimuli of
the memory set must be made. Moreover, RTs
will be longer in response to trials where two
animals have to be kept in mind (high load
condition) as compared to those where only
one animal must be memorized. This implies
that RTs will be longest in the high memory
load nontarget condition.
Accuracy measures are the percentages of
targets missed in the low-load (PM1) and
high-load (PM2) condition as well as the per-
centages of false alarms to nontarget trials in
both load conditions (PF1 and PF2). Measures
of processing speed are mean RTs of the cor-
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rect responses to targets (hits) in both load
conditions (RTHL1 and RTHL2) and mean RTs
of the correct rejections of nontargets (RTCRL1
and RTCRL2). The divided attention task was
always administered after the focused atten-
tion task.
Data analysis
Analyses were carried out for only those
children that had valid task measures. These
were defined as having percentages of errors
smaller than 50% in any of the task conditions,
given that higher error rates might reflect ran-
dom pressing of the response buttons leading
to noninterpretable effects of the task manipu-
lations. Children with valid measures were
compared to those with nonvalid measures on
a comprehensive set of baseline characteristics
(Independent-samples t-test and Pearson Chi-
square test). Statistical testing of assessment-
dependent changes and/or group differences
was confined to RTs, as error rates appeared to
be low and far from normally distributed. For
the accuracy measures therefore, only the
(condition dependent) medians are presented.
For the RT analyses, effect sizes (partial eta
squared: 2) were provided in addition to p
values because they may be more informative
when power is low due to small sample sizes.
In all tests, p values <0.05 were used to indi-
cate statistical significance.
Focused attention task
Open label phase: For those children from
whom valid measures were obtained for all as-
sessments, a repeated measures analysis of
variance (GLM, RM, SPSSPC) was applied, in-
cluding the within-subject variable “assess-
ment” with four levels (weeks 0, 4, 8, and 24)
and the within-subject variable “task” with
three levels, i.e., the three task conditions.
Contrasts were analyzed while comparing
the RTs of irrelevant targets (RTIT) with both
the RTs of relevant targets (RTIT vs. RTRT)
and the RTs of relevant nontargets (RTIT vs.
RTRNT), these contrasts being labeled “rele-
vance 1 “ and “relevance 2,” respectively. A
general medication effect on task performance
would manifest itself as a main effect “assess-
ment,” whereas a more selective effect on dis-
tractibility would be reflected by the interac-
tion “assessment by relevance.”
Discontinuation phase: A repeated measures
design was used to compare the treatment
groups including mental age as a covariate.
This design consisted of the between-subjects
variable “medication” (placebo vs. risperi-
done) and the two within-subject variables
“assessment” (week 24 vs. last visit) and “rele-
vance,” respectively. Again, two types of rele-
vance were defined as being the contrasts of,
respectively, RTIT vs. RTRT, and RTIT vs.
RTRNT. A medication effect would appear as a
difference between the groups in processing
times at the last visit as compared to week 24
(interaction “group by assessment”). If the ef-
fect would hold for especially their responses
to irrelevant stimuli, a three-way interaction
“medication by assessment by relevance”
should emerge.
Divided attention task
Open-label phase: For this task too, statistical
analyses were conducted on only the data of
subjects with valid repeated measures for all
four assessments. A repeated measurement
analysis of variance was applied with the fol-
lowing three within-subject variables: (1) “as-
sessment” with the four levels of weeks 0, 4, 8,
and 24, (2) “load” with the two levels of 1 vs. 2
animals to be kept in mind, and (3) “target”
with the two levels of target presence vs. ab-
sence in the display set. A main effect of “as-
sessment” could be indicative of a general
medication effect, whereas any interaction
with the variable “load” would reflect a more
selective effect of medication on serial search
processes.
Discontinuation phase: A repeated measures
design was used with the between-subjects
variable “medication” and the three within
subject variables “assessment,” “load,” and
“target.” Mental age was entered as a covari-
ate into the design. The “group by assess-
ment” interactions would indicate medication
effects, which, if appearing in combination
with the variable “load,” would point to serial
search processes being susceptible to the com-
pound.
564 TROOST ET AL.
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RESULTS
For the focused attention task, valid cogni-
tive measures were obtained for 15, 15, 15, 16,
and 12 out of 24 children at baseline, weeks 4,
8, 24, and week 8 after random assignment to
either placebo or risperidone, respectively. For
the divided-attention task, valid measures
were obtained for 14, 14, 18, 16, and 14 chil-
dren, respectively. The valid and nonvalid
children significantly differed at all time
points for both focused attention and divided
attention in age, mental age, and the three sub-
scales of the Vineland Adaptive Behavior
Scales (Table 1; numbers only shown for di-
vided attention at week 24).
Open label phase 
Focused attention: Of the different types of er-
rors, the greatest percentage (7.1%) was found
for the false alarms in response to irrelevant
stimuli (PFI). For the reaction times, the great-
est response latencies were found for the con-
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TABLE 1. BASELINE CHARACTERISTICS OF 24 CHILDREN ENTERING THE DISCONTINUATION PHASE
Divided attention task
Valid (n = 14) Non valid (n = 10) pb
Risperidone Placebo Risperidone (n = 5)
Characteristic (n = 7) (n = 7) pa and placebo (n = 5)
Age, mean (SD) 11.3 (3.2) 9.0 (1.2) 0.116 7.5 (1.4) 0.004c
Mental age 9.45 (2.9) 8.42 (2.2) 0.431 6.4 (0.4) 0.002c
Male/female, n (%) 6/1 (86/14) 6/1 (86/14) 1.00 10/0 (100/0) 0.212
DSM-IV TR diagnosis of PDD, n (%) 0.580 0.314
Autistic disorder 1 (14) 1 (14) 4 (25)
Asperger’s disorder — 1 (14) 1 (10)
PDD not otherwise specified 6 (86) 5 (71) 5 (50)
Score on Vineland Adaptive Behavior
Scales, mean (SD)
Communication 104.3 (16.6) 109.3 (11.3) 0.524 82.2 (24.9) 0.014c
Socialization 88.9 (12.6) 83.9 (15.5) 0.522 59.5 (18.4) 0.001c
Daily Living 119.9 (13.9) 121.7 (13.2) 0.801 95.3 (24.0) 0.009c
Concomitant medication status, n (%) 0.513 0.180
None 5 6 —
Stimulant 1 2 —
Stimulant and anticonvulsant 1 — —
Weight, kg, mean (SD) 47.4 (16.7) 37.7 (10.7) 0.221 35.5 (7.0) 0.127
Daily doses, mg, mean (SD) 1.7 (.64) 1.6 (.38) 0.804 2.0 (.71) 0.237
Score on Aberrant Behavior Checklist,
mean (SD)
Irritability 11.3 (10.7) 10.6 (8.3) 0.891 13.2 (.187) 0.455
Social Withdrawal 5.0 (7.1) 6.7 (6.0) 0.656 5.8 (6.0) 0.983
Stereotypy 2.0 (2.6) 4.9 (5.0) 0.213 3.6 (3.8) 0.917
Hyperactivity 13.4 (10.9) 13.0 (10.8) 0.942 20.6 (8.9) 0.076
Inappropiate Speech 2.1 (1.6) 1.6 (1.3) 0.470 3.9 (3.4) 0.101
Clinical Global Impressions, n (%) 0.534
Minimally Improved 2 (29) 1 (14) 5 (50) 0.336
Much Improved 3 (43) 3 (43) 3 (33) 0.336
Very Much Improved 2 (29) 3 (43) 2 (20) 0.336
PDD = Pervasive developmental disorder; CGI = Clinical Global Impressions (Guy 1976); ABC=Aberrant Behavior
Checklist (Aman 1985).
ap differences in baseline descriptions between valid and nonvalid groups.
bp differences in baseline descriptions between placebo and risperidone groups with valid Divided Attention Tasks
(independent-samples t-test for continuous variables and Pearson Chi-square test for categorical variables, two-
sided).
cSignificant.
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dition where irrelevant information had to be
ignored (RTIT), whereas children responded
much faster to relevant targets (RTRT). Re-
sponse latencies for the rejection of relevant
nontargets (RTRNT) were found to lie in be-
tween these two conditions. In all the three
conditions, RTs became shorter with increas-
ing time of assessment (Table 2).
Analyses of variance (n = 11) revealed signif-
icant assessment effects for the RTs of all three
conditions, this being greatest for the rejection
times of irrelevant targets showing a high ef-
fect size of 2 = 0.69. There was a significant
difference between RTs for correctly rejecting
irrelevant targets (RTIT) and correctly re-
sponding to relevant targets (RTRT), having a
high effect size of 2 = 0.59 (Table 2, Relevance
1). The difference between response times for
correctly rejecting irrelevant targets and cor-
rectly rejecting relevant nontargets (Relevance
2) did not appear to be statistically significant.
Finally, there was a significant two-way in-
teraction between RT differences for relevant
and irrelevant targets (Table 2, Relevance 1)
and the time of assessment, indicating that the
differences indeed became smaller with pro-
longed risperidone treatment. This interaction
had an effect size of 2 = 0.46. For the second
type of the relevance manipulation (Table 2,
Relevance 2), the assessment dependent de-
crease was not found to be statistically signifi-
cant though the effect size was moderate (2 =
0.13).
Divided attention: With regard to accuracy,
relatively more targets were missed (PM1/
PM2) than false alarms to nontargets had been
given (PF1/PF2). In general, error percentages
were rather low, with the highest percentage
referring to the targets missed in the high load
condition (11%). No systematic decrease with
increasing time of assessment could be ob-
served.
With respect to processing speed, for each
assessment, RTs increased from the low-load
target (RTHL1) to the high-load nontarget
(RTCRL2) condition. Moreover, RTs decreased
from baseline to week 24 as well as from base-
line to week 8; these decreases, however, were
only small for the low-load conditions (RTHL1
and RTCRL1). Of note, the steepest decreases
were found from baseline to the first assess-
ment after baseline at week 4. From this time-
point on, RTs did not show any further re-
markable changes (Table 2).
When testing task manipulation and assess-
ment effects (n = 11), a significant assessment
effect was found only for the high-load target
condition (RTHL2), with a high-effect size of
2 = 0.71. The decrease in RTs of the high-load
nontarget condition did not reach statistical
significance, although it showed a high-effect
size too (2 = 0.18). Concerning the task ma-
nipulation effects, there were significant dif-
ferences between the high-load and low-load
as well as between the nontarget and target re-
sponse times when pooled across the various
assessments. Both “load” and “target” effects
turned out to be statistically significant with
high effect sizes of 2 = 0.78 and 2 = 0.80, re-
spectively.
When finally turning to the question of
whether the effects of the task manipulations
became smaller with increasing time of assess-
ment, a significant interaction was found
between the “load” manipulation and “assess-
ment,” with a high-effect size (2 = 0.65) indi-
cating that the impact on memory search
processes indeed became lower. The three-way
interaction “load by target by assessment” was
not found to be significant, although it turned
out to have a high effect size (2 = 0.21).
Discontinuation phase
Focused attention: Twelve out of 24 children
had valid measures at both assessments. Of
the 12 children with valid measures, there
were no significant differences in the two
treatment groups (i.e., risperidone vs. placebo)
with respect to clinical, developmental, and
demographic characteristics (Table 1; numbers
only shown for the divided attention task).
There was no increase of RTs from week 24
to the last visit for the placebo group (Fig. 1).
Whereas both types of the “relevance” manip-
ulation showed significant effects, there were
no interactions with the group (“medication”)
and assessment variable (Table 3A).
Divided attention: Of the 14 children with
valid measures, there were no significant dif-
ferences in the two treatment groups with re-
spect to baseline characteristics (Table 1).
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FIG. 1. Focused attention task: Reaction times irrelevant targets (RTIT) for each subject in the discontinuation
phase.
FIG. 2. Divided attention task: Reaction times correct rejections high-load condition (RTCRL2) for each subject in
the discontinuation phase.
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Mean RTs increased from week 24 to the last
visit assessment for only the placebo group,
whereas a further decrease in the group that
continued on risperidone was observed (Fig.
2). The greatest increase was observed for
the high-load exhaustive memory search con-
dition (RTCRL2). The corresponding interac-
tion (“medication by assessment”), however,
showed a smaller effect size than the interac-
tion corresponding with changes in low load
RTs (RTL1). Yet, the latter interactions were ac-
tually caused by relatively greater RT decreases
in the risperidone group than increases shown
in the placebo group. When testing the changes
in the high-load nontarget search condition
(RTCRL2) for both groups separately, we found
a nonsignificant increase (p = 0.34) with yet a
high-effect size (2 = 0.15) for the placebo
group, and a trend-level significant decrease
for the risperidone group (p = 0.06; 2 = 0.46).
However, the above-suggested larger effect on
especially the high-load conditions was not
confirmed by three- or four-way interactions
including the task variable “load” (Table 3B).
DISCUSSION
This study was the first to have evaluated
neuropsychological effects of risperidone in
children and adolescents with PDDs. Our re-
sults suggest a beneficial effect of long-term
treatment with risperidone on cognitive func-
tioning, especially with regard to processes
that make a demand on working memory.
For both the focused and divided atten-
tion tasks, it was demonstrated that the ma-
nipulations of, respectively, distractibility by
irrelevant information and working memory-
related serial search processes were successful,
showing that task performances indeed were
valid with the consequence that assessment-
related changes could be interpreted in terms
of the measurement pretensions.
Repeated testing during the open-label
phase resulted in improved performance, indi-
cating that potentially sedating side effects do
not impair attention-related information pro-
cessing during a treatment period of several
months. The improved performance could be
due to practice effects, maturity, or effects of
risperidone over time. Because of the uncon-
trolled nature of the first part of the study, it
was not possible to conclude which element or
combination of elements was responsible.
However, regarding divided attention in the
controlled discontinuation phase, the children
maintained on risperidone performed better
than those switched to placebo, suggesting at
least some long-term drug effect in enhancing
working memory performance.   
A risperidone-associated effect on focused
attention was not apparent from our data.
Here, a significant assessment-dependent de-
crease in the effect of distracting information
was found on processing times during the
open-label phase, whereas, however, reaction
times did not significantly worsen in the
placebo group during the discontinuation
part. This suggests that the use of risperidone
does not interfere with learning to neglect ir-
relevant information when such a task is re-
peatedly administered. Interestingly, focused
attention has repeatedly been found unaf-
fected in children with PDDs while using simi-
lar task paradigms (Althaus et al. 1996;
Ozonoff and Jensen 1999). This may explain
the lack of regression in the placebo group: If
these children (just as those of the other group)
did not start with an essentially deficient level
of distractibility, they just might have re-
mained at the level reached by learning.
Some of the deterioration in the discontinu-
ation phase might have been due to acute
withdrawal effects rather than simply the ab-
sence of risperidone. However, as previously
described (Troost et al. 2005), time between
week 24 and last visit was, on average, 6 ± 1
weeks for placebo and 7 ± 1 for risperidone,
making deterioration due to acute withdrawal
effects after 3 weeks of gradual taper and an-
other 3 weeks of completely stopping risperi-
done less likely.
Deficient working memory performance has
repeatedly been suggested to characterize chil-
dren with a PDD (Althaus et al. 1996; Bennetto
et al. 1996; Pennington and Ozonoff 1996;
Landa and Goldberg 2005) and may arise from
structural or functional deviations of the ante-
rior cingulate gyrus (Posner and Raichle 1994;
570 TROOST ET AL.
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Haznedar et al. 2000; Luna et al. 2002; Levitt et
al. 2003; Koshino et al. 2005; Zarahn et al.
2005). The anterior cingulate gyrus has a high
serotonin receptor density (Haznedar et al.
1997), and an imbalance in serotonin neuro-
transmission has been associated with cogni-
tive and behavioral manifestations of autism
(Piven et al. 1991). In this context, it could be
speculated that a possible role of risperidone
(a potent postsynaptic dopamine and seroto-
nin receptor blocker) in enhancing working
memory processes in PDDs may be mediated
through a serotonergic effect in this brain area.
A clear limitation of this study was that a
large proportion of the children was not able
to perform the two tasks well enough to be
considered valid task performers. The children
with nonvalid measures were of younger chro-
nological and mental age and had lower adap-
tive skills. This demonstrates that younger
children with PDDs and co-morbid disruptive
behavior who show lower levels of adaptive
skills are less capable of performing ade-
quately on the computerized tasks as used in
this trial. Their drop-out from further analyses
not only led to relatively small sample sizes
(although effect sizes still were high), but also
may have confined the generalizability of the
results to children of older age with higher lev-
els of functioning. These findings clearly need
replication with larger samples, using care-
fully selected cognitive measures. However,
given that cognitive function is one of the
more difficult domains to engage in PDDs,
the testable rate of approximately 50% still is
very favorable and probably would have been
lower if a larger proportion of the children in
this sample had an autistic disorder. Therefore,
these preliminary findings certainly contrib-
ute to the sparse literature on the cognitive ef-
fects of risperidone in children with PDDs and
demonstrate that many such children are in
fact testable.
In conclusion, the present study suggests a
possible additional benefit of risperidone in
low-to-intermediate doses in enhancing work-
ing memory performance in children with
PDDs. This may be associated with improve-
ments in social, communicative, and academic
functioning.
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